Cancer 52, an alliance of over 90 organisations, united in improving the future for everyone affected by rare and less common cancers, has published the results of its patient survey in which many mesothelioma patients took part.
This patient survey looked at the impact of the Covid-19 pandemic on people with rare and less common cancers ran from early December 2020 to mid-January 2021. Over 500 people from across England responded. Some of the key findings included:
• People diagnosed since the pandemic faced delays – either because they were concerned about contacting their GP or test and scans had been delayed
• One in ten people who had received treatment since the pandemic began had not had the type of treatment they were expecting to receive
• One in ten people had not been able to access their GP during the pandemic. 20% had been able to see their GP in person and 70% had been able to have a virtual or telephone appointment
The results can be seen at www.cancer52.org.uk/single-post/cancer52-publishes-england-results-of-its-second-patient-survey and are also being shared with NHS England, and other key stakeholders in the charity sector and industry.